DGI Top Bar

 

 

DGI Focus —

DGI is focused on gene therapies for diseases of the blood, including Fanconi Anemia, Hemophilia A and AIDs. We are in the process of filing an Initial New Drug (IND) application as we prepare for clinical trials for Fanconi Anemia.

 


DGI SB-THERAPEUTICS PIPELINE

Current Focus

(Orphan Diseases)
Disease Gene Market DGI Advantages
Fanconi Anemia
(ready for clinical trials)
Fanc-C &
Fanc-A
>$300 M IND & Orphan Drug filing in progress; SBIR funding; patients available.
Hemophilia A

 

Factor VIII >$500 M SBIR funding; DGI partners.
(Orphan Disease) Brain Tumors IL13-HSVTK $2 B/yr Founder's discovery

R & D

Cancer

 

EC2-peptide* $4-5 B/yr Patent filed.
Ischemia

 

AN1*, SRP1*, AN2*, EC1*, EC2* $10 B/yr Patents filed.
AIDS

 

siRNAs >$10 B/yr
* DGI Proprietary Patent Pending Biologicals

©2004-2006 Discovery Genomics, Inc. • 614 McKinley Pl. N.E., Minneapolis, MN 55413 • ph/612-656-4484 • fax/612-379-6580